Celularity Inc. Overview
Pro stress-test →Celularity Inc. is a regenerative and cellular medicines company focusing on addressing aging-related and degenerative diseases. The company develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease.
Strategic Profile
Pro stress-test →The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Recently, Celularity completed a significant balance sheet restructuring by retiring $41.6 million in senior secured debt while maintaining exclusive licensing rights to its intellectual property for 5 years.
Competitive Landscape
Pro stress-test →Celularity's therapeutic programs target aging-related diseases using mesenchymal-like adherent stromal cells, CAR T-cells, and natural killer (NK) cells. The company competes in the broader regenerative medicine and cell therapy space against established biotech firms and emerging cell therapy developers, differentiated by its exclusive access to placental-derived material sources.
Industry Context
Celularity Inc. operates in Regenerative Medicine & Cell Therapy (Biotech).
Key facts
Founded: 2018 · Headquarters: Florham Park, New Jersey, US · Revenue: $54.2M (2024) · Market cap: $45M